Valbiotis SA (FR:ALVAL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Valbiotis SA is set to launch its innovative dietary supplement, Valbiotis®PRO Metabolic Health, in France by early 2025. This plant-based product targets metabolic disorders like dysglycemia and type 2 diabetes, with its effectiveness backed by extensive clinical testing. The company aims to leverage the successful strategy of its previous product, Valbiotis®PRO Cholesterol, for this launch.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.